retifanlimab
Sign in to saveAlso known as Zynyz
Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma. Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
In the Vinony graph
Vinony's link graph records 371 inbound references to retifanlimab, and connects out to monoclonal antibody, fusion protein and humanized antibody.
It sits within the topics Chemical pages without ChemSpiderID, Drugs that are a monoclonal antibody and Drugs with non-standard legal status.
Vinony links it to 8 Wikipedia language editions.
~3 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse effects
- History
- Society and culture
- Legal status
- Names
- References
- External links
Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma. Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
It was approved for medical use in the United States in March 2023, and in the European Union in April 2024.
Excerpted from Wikipedia’s “retifanlimab” article, available under the CC BY-SA 4.0 licence.